The Royal Academy of Engineering organised an invite only #BreakTheBias breakfast with guest speakers Naomi Springate, Director Enterprise Assurance at TSB Bank and Maria Dramalioti-Taylor, Founding Partner of Beacon Capital who sits on the board of several portfolio companies, to celebrate International Women's Day. The event was organised by the Enterprise Hub and highlighted the benefits and value of diverse boards and leadership and explored trends and attitudes within the investment community. The intimate gathering not only celebrated women in engineering but also provided an opportunity to network with fellow Hub Members and the Enterprise Hub network. The female members of MediSieve's team enjoyed the event immensely and are already looking forward to next year. 

A further connection with the community of RAEng was nurtured by MediSieve's CEO, George Frodsham. George participated in a RAEng roundtable with Sir David Grant as part of his independent review of UK Research and Innovation (UKRI). UKRI is the umbrella organisation that includes the seven disciplinary research councils, Research England and Innovate UK. Sir David has been asked to investigate if UKRI is achieving its core objectives and assess its readiness to contribute to the UK government’s ambitions. The results are expected to be published in the summer of 2022. Being invited to the roundtable is a tremendous honour and distinction for both George and MediSieve as a company.

Lastly, MediSieve's CTO Cristina Blanco-Andujar connected with the community at UCL that gave start to MediSieve. Cristina spoke at UCL's Biology and Business event as part of UCL's Themed Life Science Week. The events during Themed Weeks involve a mix of panel discussions, presentations, and skills workshops, providing students an ideal opportunity to learn more about a particular sector. MediSieve cannot wait to see new exciting projects emerge from within the university's walls - just like MediSieve did a few years ago. Cristina has said that

" These types of events are great to provide visibility on career opportunities and potential paths to students. Furthermore, this is a way to give back to those institutions that have offered support in the company's journey."

Reconnecting and giving back to the communities that supported MediSieve from the start is rewarding not only for publicity purposes but on a personal level as well. The team hope to continue building and nurturing a strong connection with both RAEng and UCL.

A recording of the Biology and Business Forum as well as more about UCL's Themed Weeks can be found here:

https://www.ucl.ac.uk/careers/resources/themed-weeks-archive/careers-life-science-industry-week

About Magnetic Blood Filtration 

MediSieve's Magnetic Blood Filtration Platform is intended to enable the rapid and specific depletion of specific agents from the bloodstream of patients. The extracorporeal therapy uses therapeutic Magnetic Beads that are designed to bind specifically to the clinical target. The Beads are introduced into the extracorporeal circuit during the therapy, mixing with the patient’s blood and binding to the clinical targets. The Delivery Platform captures all the Magnetic Beads and bound targets, preventing their return to the patient.

About MediSieve

MediSieve is a London-based BioTech start-up that has developed Magnetic Blood Filtration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. The company is a spin-off from University College London and is developing its products at the White City Innovation District in West London. MediSieve is actively seeking investment and partnerships.

MEDIA CONTACT:

Alina Kagermazova

alina@medisieve.co.uk

INVESTOR AND PARTNERSHIP CONTACT:

George Frodsham

george@medisieve.co.uk